A physician haunted by a dying child’s gasping breath helped transform a fatal disease into a condition where patients now live into their fifties, proving that one doctor’s obsession can rewrite medical destiny for thousands.
Story Snapshot
- Dr. Michael Welsh turned cystic fibrosis from a childhood death sentence into a manageable condition through decades of genetic research at the University of Iowa
- His work led to Trikafta, a breakthrough drug approved in 2019 that now helps 90% of CF patients regain near-normal lung function and life expectancy
- A chance encounter in an Iowa City bar between Welsh and CF patient William O’Neal II revealed the deeply personal impact of his scientific revolution
- The treatment costs $300,000 annually, raising serious questions about access despite its transformative power
The Encounter That Changed Everything
During his medical training in the 1970s at the University of Iowa Carver College of Medicine, Michael Welsh watched a young girl with cystic fibrosis struggle for every breath. She was dying, and medicine offered nothing. That image seared itself into his consciousness, redirecting his career from general medicine to pulmonary research focused on the ion channel defects that make CF patients drown in their own mucus. The girl represented thousands of children who rarely saw their tenth birthday, victims of a genetic mutation that turned their lungs into death traps.
Cracking the Genetic Code
Welsh’s laboratory helped clone the CFTR gene in 1989, working alongside scientific heavyweights Lap-Chee Tsui and Francis Collins. This discovery identified the precise genetic mutation causing cystic fibrosis, but knowing the enemy and defeating it remained vastly different challenges. The gene discovery opened a pathway that would take another three decades to traverse. Welsh co-founded the cystic fibrosis program at Vertex Pharmaceuticals, betting that modulator drugs could fix the defective protein rather than just treating symptoms. The Cystic Fibrosis Foundation invested over twenty million dollars in this moonshot approach.
The Drug Pipeline That Saved Lives
Kalydeco arrived in 2012 as the first CFTR modulator, helping four to five percent of patients with specific mutations. Orkambi followed in 2015, then Symdeko in 2018, each iteration reaching more patients but still leaving the majority behind. Then came Trikafta in 2019. This triple-combination therapy targeted ninety percent of CF mutations, delivering results that seemed impossible just years earlier. Patients gained ten to twenty points in lung function tests. Hospitalizations dropped sixty to seventy percent. The average life expectancy, which had crept from single digits to the thirties over previous decades, suddenly jumped past fifty years.
When Science Meets Poetry in a Bar
William O’Neal II, a poet from the Iowa Writers’ Workshop, nearly died from cystic fibrosis before Trikafta gave him his breath back. His family had prayed for a miracle while he gasped through his twenties and thirties. One evening in an Iowa City bar, O’Neal found himself sitting next to an older gentleman. Conversation revealed the stranger was Michael Welsh, the researcher whose life’s work had saved O’Neal’s life. The moment captures something beyond statistics: Welsh’s science transformed abstract genetic mutations into breathing human beings who write poetry, raise grandchildren, and live normal lives.
The Price of Breathing
Trikafta generated $8.4 billion in revenue for Vertex Pharmaceuticals in 2023, charging roughly $300,000 per patient annually. This creates an uncomfortable tension between miraculous outcomes and crushing economics. Patients in wealthy nations breathe freely while those in developing countries still face the old death sentences. Critics point to access barriers that exclude millions globally from this functional cure. Defenders counter that orphan drug development requires massive investment with uncertain returns. Welsh himself noted in a 2023 interview that Trikafta gives patients back normal lives, though he carefully avoided calling it a cure.
The Broader Medical Revolution
Welsh’s cystic fibrosis breakthrough became a template for precision medicine, proving that genetic modulators could treat diseases at their molecular root. The FDA accelerated approval processes based on CF successes. Pharmaceutical companies shifted billions toward genetic therapies for sickle cell disease, muscular dystrophy, and rare metabolic disorders. The venture philanthropy model pioneered by the Cystic Fibrosis Foundation showed how patient advocacy organizations could fund high-risk research that traditional grants avoided. Robert Knowles from the University of North Carolina called Welsh’s CFTR work paradigm-shifting, fundamentally changing how medicine approaches genetic diseases.
As of 2026, Welsh continues his research at the University of Iowa, now focused on the remaining ten percent of CF patients with rare mutations that current drugs cannot address. Vertex received FDA approval for vanzacaftor in 2024, offering once-daily dosing with similar efficacy to Trikafta. Ongoing trials explore mRNA approaches and treatments for infants, pushing toward earlier intervention. Approximately forty thousand Americans with cystic fibrosis now have access to modulator therapies, a stunning reversal from the hopeless prognosis Welsh witnessed five decades ago. The physician who could not save one gasping child created the science that saved tens of thousands.
Sources:
How We Help the Body Breathe – NIH Circulating Now
